Documents

Romaciclib demonstrates strong clinical promise in AML and MF, driving accelerated development.

Romaciclib demonstrates strong clinical promise in AML and MF, backed by key partnerships and funding.

Romaciclib demonstrates promising efficacy in AML, driving accelerated development and global expansion.

Net loss narrowed and cash reserves remain strong, with new grants and collaborations secured.

Romaciclib delivers promising results in AML and MF, driving a robust oncology pipeline.

Romaciclib delivers promising results in AML and MF, driving a robust oncology pipeline and partnerships.

Romaciclib delivers promising results in AML and MF, with a robust pipeline and strong partnerships.

Revenue fell and losses increased, but pipeline progress and new funding support future prospects.

Net loss widened on lower R&D revenue and NodThera revaluation; cash runway extended to H2 2026.

Q1 2025 net loss deepens to PLN 25.3m, with strong liquidity supporting operations to H2 2026.

RVU120 and MEN1703 drive Ryvu's oncology pipeline, with key data readouts expected in 2025.

Revenue up, net loss widened; cash runway extended to H2 2026 after reorganization.

RVU120 Phase II trials show early efficacy and safety, with key data expected in 2025.

Operating revenue and cash rose, but net loss widened as clinical pipeline advanced.

Ryvu drives innovation in oncology with first-in-class therapies and global clinical programs.

Revenue up 43% year-over-year, net loss widens, pipeline and cash position strengthened.

Advancing first-in-class oncology therapies, Ryvu targets major hematology markets with global ambitions.